Vascular and non-vascular approaches to the treatment of stroke

ISSN： 1472-8214

Source： Expert Opinion on Emerging Drugs, Vol.3, Iss.1, 1998-06, pp. : 55-66

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Stroke is the third leading cause of death in the Western world and a major burden on healthcare systems. Current treatment is primarily limited to anticoagulant or antiplatelet therapy for primary or secondary prevention of stroke. A small number of ischaemic stroke patients are eligible for thrombolytic therapy with tissue plasminogen activator (t-PA) but this has to be administered within 3 hours of the ischaemic event. A large number of agents are currently under development for stroke. Recently, a number of new compounds have failed to show positive effects in Phase III trials in ischaemic stroke. In many cases the reasons for this are not clear; however, some could have been predicted. However, much has been learnt about the design and implementation of clinical trials for neuroprotective agents as a consequence of these studies.